FinnCap Reaffirms “Corporate” Rating for OptiBiotix Health (LON:OPTI)

FinnCap reissued their corporate rating on shares of OptiBiotix Health (LON:OPTI) in a research note issued to investors on Tuesday, December 12th.

Shares of OptiBiotix Health (OPTI) opened at GBX 64.50 ($0.86) on Tuesday. OptiBiotix Health has a one year low of GBX 59 ($0.79) and a one year high of GBX 90 ($1.20). The stock has a market cap of $51.99 and a price-to-earnings ratio of 2,150.00.

TRADEMARK VIOLATION NOTICE: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at

About OptiBiotix Health

Optibiotix Health Plc is a life sciences company developing a range of products to modify the human microbiome. The Company’s principal activity is research and development into microbiome modulators. It operates in UK segment. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression.

Receive News & Ratings for OptiBiotix Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiBiotix Health and related companies with's FREE daily email newsletter.

Leave a Reply